Compare Global Payments Inc (GPN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Tango Therapeutics Inc. — how do they compare? Global Payments Inc trades at $80.89 (market cap $21.67B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Global Payments Inc is far larger — about 5.8× Tango Therapeutics Inc.'s market cap, and Global Payments Inc pays a 1.22% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Tango Therapeutics Inc. for 0 Days on average.
| GPN | TNGX | |
|---|---|---|
Market Cap | $21.67B | $3.75B |
Volume | 1,851,678 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $94.83 | $32.90 |
52-Week Low | $62.47 | $7.50 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $39.81B | $2.77B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $80.89, down 1.43% on the day, with a neutral technical outlook despite recent earnings beats. The company shows strong revenue growth momentum with Q2 2026 EPS of $3.46 beating estimates, while maintaining a P/E of 38.81 and P/B below 1.0. Recent developments include the Genius platform rollout and Worldpay integration driving business expansion.
The stock offers 27% upside to the $102.75 consensus price target with strong analyst support (59% buy ratings), though negative net income margin and rising debt-to-asset ratio to 41.57% present execution risks. Key catalysts include continued Genius adoption while competition and cost pressures remain headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
